ATC Group: C07AA03 Pindolol

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C07AA03 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C07 Beta blocking agents
3 C07A Beta blocking agents
4 C07AA Beta blocking agents, non-selective
5 C07AA03 Pindolol

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 15 mg
PAREN - Parenteral 15 mg

Active ingredients in C07AA03

Active Ingredient Description
Pindolol

Pindolol is a potent beta-adrenoceptor antagonist (beta-blocker) with uses similar to those of propranolol. It is classified as non cardioselective. It blocks both B1- and B2-adrenoceptors for more than 24 hours after administration. It has negligible membrane-stabilising activity. Pindolol exhibits low cardiodepressant activity at therapeutic dose.

Medicines in this ATC group

Australia (AU)

Brazil (BR)

Canada (CA)

France (FR)

Germany (DE)

Japan (JP)

Mexico (MX)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.